Cardiovascular toxicities associated with bispecific T-cell engager therapy
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated with BTEs.Methods Leveraging the US Food and D...
Saved in:
| Main Authors: | Ahmed Sayed, Malak Munir, Eric H Yang, Daniel Addison, Sarah Khan, Jiwon Kim, Syed Mahmood, Narendranath Epperla, Alexa Meara, Sanam M Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sneha Sharma, Stephanie Feldman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-02-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/2/e008518.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi et al
by: Ahmed Sayed, et al.
Published: (2024-04-01) -
Cardiovascular toxicities associated with novel cellular immune therapies
by: Malak Munir, et al.
Published: (2024-12-01) -
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study
by: John L. Vaughn, et al.
Published: (2024-11-01) -
A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024-12-01) -
Developability considerations for bispecific and multispecific antibodies
by: Alaa Amash, et al.
Published: (2024-12-01)